典型前列腺腺癌与罕见组织学变异型前列腺癌的特征及预后比较:基于监测、流行病学和最终结果数据库的分析
基于监测、流行病学和最终结果(SEER)数据库(2004—2016年),纳入780例(3.3%)组织学变异型前列腺癌患者和235834例典型腺癌患者,比较其临床特征与预后。变异型组分期较典型腺癌组更晚,神经内分泌前列腺癌更易发生内脏转移;除黏液型外,变异型预后均差于典型腺癌,低前列腺特异性抗原水平的神经内分泌前列腺癌患者生存最差,黏液型总生存与典型腺癌相似。
要点
- 变异型组分期较典型腺癌组更晚,神经内分泌前列腺癌更易发生内脏转移。
- 除黏液型外,变异型预后均差于典型腺癌;黏液型总生存与典型腺癌相似。
- 低前列腺特异性抗原水平的神经内分泌前列腺癌患者生存最差。
核心结论
- 组织学变异型前列腺癌较典型腺癌分期更晚,除黏液型外预后更差,低前列腺特异性抗原水平的神经内分泌前列腺癌患者生存最差。
- 作者建议神经内分泌前列腺癌患者应尽快接受积极治疗以改善预后。
- 作者认为仍需进一步研究以明确黏液型前列腺癌相较典型腺癌在患者预后中的作用。
研究设计与样本
- 基于监测、流行病学和最终结果(SEER)数据库(2004—2016年)的分析,纳入780例(3.3%)组织学变异型前列腺癌患者和235834例典型腺癌患者。
主要发现
- 变异型组分期较典型腺癌组更晚。
- 神经内分泌前列腺癌患者更易发生内脏转移。
- 除黏液型外,变异型预后均差于典型腺癌。
- 低前列腺特异性抗原水平的神经内分泌前列腺癌患者生存最差。
- 黏液型前列腺癌总生存与典型腺癌相似。
临床怎么用
- 作者建议神经内分泌前列腺癌患者应尽快接受积极治疗以改善预后。
- 作者认为仍需进一步研究以明确黏液型前列腺癌相较典型腺癌在患者预后中的作用。
局限性
- 作者认为仍需进一步研究以明确黏液型前列腺癌相较典型腺癌在患者预后中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are currently few large-scale studies describing the clinical characteristics of these histological variants of prostate cancer (PCa) and the prognostic results of these patients. Thus, we used the Surveillance, Epidemiology, and End Results (SEER) database to achieve a more comprehensive understanding of the current prevalence and prognosis of these histological variants. A total of 780 (3.3%) patients with histological variants and 235834 patients with typical adenocarcinoma were included in the present study. The variants group presented with a more advanced stage than the typical adenocarcinoma group. The results also showed that patients with neuroendocrine (NE) PCa were more likely to have visceral metastases. In prognostic comparison, we found that variants, except for mucinous, had a worse prognosis than typical adenocarcinoma. Moreover, among these variants, we also discovered that NEPCa patients with low prostate-specific antigen level had the worst survival. In contrast, mucinous PCa had similar overall survival to typical adenocarcinoma. PATIENT SUMMARY: We reported follow-up results for prostate cancer (PCa) patients from the Surveillance, Epidemiology, and End Results database (2004-2016). We focused on the prognosis of PCa with different histological variants and evaluated the risk factors that were significant in predicting poor prognosis. We suggested that neuroendocrine PCa patients should receive active treatment as soon as possible to improve their prognosis. We still need further studies to identify the role of mucinous PCa in patients' prognosis compared with typical adenocarcinoma.
引用
- Zhou J, Ding J, Qi J, et al. Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis. Eur Urol. 2022. PMID: 35221166. doi:10.1016/j.eururo.2022.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。